Axio Biosolutions Pvt Ltd news

India’s homegrown integrated woundcare company, Axio Biosolutions today announced that it has completed its ESOP Buy back program of half a million US Dollars from current and past employees. This buyback is on back of its recent Series B2 fund raise of $6mn last year.

Under this liquidation, eligible past and current employees have been able to liquidate their vested ESOPs for a combined value of USD 0.5 million. Employees irrespective of their job profile or tenure have been p

Axio Biosolutions, a pioneering MedTech company, today announced a $6 million Series B2 equity raise led by TrueScale Capital, with participation from existing investors Omidyar Network India, University of California– Ratan Tata Fund, and Accel. Axio Biosolutions Private Limited, India (“Axio”), a wholly owned subsidiary of Boston-based Advamedica Inc. is a leading developer of hemostatic and advanced wound care products. Sameer Nath, Managing Partner at TrueScale Capital,

Axio Biosolutions, an integrated wound care company has announced FDA 510(k) clearance of its hemostatic product, Axiostat Patch that helps control moderate to severe bleeding in vascular procedures, surgical debridement sites, puncture sites and more.

Axiostat Hemostatic Patch is based on a protonated bioadhesive technology which works by providing a strong mechanical barrier to the injury site. It controls bleeding from puncture sites within minutes of application, providing a barri